Sanofi/Genzyme expect US Lemtrada decision in 2nd half, while Aubagio's footprint growing
This article was originally published in Scrip
Executive Summary
If things go smoothly from this point on, Genzyme and its parent company Sanofi could have a decision from the US FDA in the second half of this year on the firms’ supplemental biologics license application (sBLA) to market Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis (RMS), with the medicine granted a standard review.